Previous reports have shown that circulating CXCL14 protein levels are significantly higher in plasma from patients with IPF than in controls, and circulating CXCL14 levels are significantly reduced upon vismodegib treatment in patients with cancer, indicating that circulating CXCL14 levels can reflect hedgehog pathway signaling in some settings [16]. Here, CXCL14 is linked to cancer.